Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Conditions
Keywords
platinum-sensitive recurrence, carboplatin, pemetrexed
Brief summary
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Detailed description
* Before patients receive any chemotherapy treatments they will be given three medications to prevent side effects from the chemotherapy drugs. These medications are vitamin B12, folic acid and dexamethasone. * Chemotherapy treatments will be given intravenously in the outpatient clinic. Pemetrexed will be given first and will take 10 minutes to infuse followed by carboplatin which will take 30-45 minutes to infuse. These treatments will be repeated once every three weeks for 6 cycles of chemotherapy (18 weeks). * Before each chemotherapy treatment the following tests and procedures will be performed: physical exam and medical history; evaluation of ability to undertake daily activities; and blood tests. * After every 2 cycles of chemotherapy (every 6 weeks) patients will have a CT or MRI scan to measure how well their cancer is responding to treatment. * The study treatment will last for 6 cycles of chemotherapy as long as the tumor does not grow and the patient isn't experiencing any severe side effects.
Interventions
DRUGCarboplatin
Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
DRUGPemetrexed
Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
Sponsors
Massachusetts General Hospital
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of platinum-sensitive recurrence of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer * The following histologic subtypes are eligible: papillary serous, endometrioid, mucinous, clear cell, adenocarcinomas, transitional, and mixtures of the above. * At least one measurable lesion according to RECIST criteria via CT or MRI scan * Received a platinum-containing regimen at initial diagnosis * ECOG performance status of 0,1 or 2 * 18 years of age or older * Life expectancy of greater than 12 weeks * WBC \> 1,500/mm3 * Neutrophils \> 1,500/mm3 * Platelets \> 100,000/mm3 * Total Bilirubin \< 1.5 ULN * Calculated creatinine clearance \> 45 ml/min * ALT/AST \< 3 x ULN (no liver mets) ALT/AST \< 5 x ULN (with liver mets) * Complete recovery from completion of previous chemotherapy or biologic therapy * Negative pregnancy test and agree to practice effective method of birth control
Exclusion criteria
* Patients with sarcomatous, stromal, or germ cell elements * Prior pelvic radiotherapy \> 25% of bone marrow * Uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs * Past history of bone marrow transplantation or stem cell support * Known history of CNS metastasis unless the patient has had treatment with surgery or radiation therapy, is neurologically stable, and does not require oral or intravenous corticosteroids or anticonvulsants * Prior malignancy except adequately treated carcinoma in situ of the uterine cervix, incidental stage I endometrial cancer, basal cell or squamous cell skin cancer or breast cancer (invasive or ductal carcinoma in situ) of which the patient has been disease-free for at least five years * Routine prophylactic use of G-CSF or GM-CSF or blood transfusions within 2 weeks * Clinically significant cardiac disease as defined by: history of unstable angina within 6 months; history of symptomatic ventricular arrhythmias; history of congestive heart failure; history of myocardial infarction within 6 months * Uncontrolled hypercalcemia or diabetes mellitus * Any signs of intestinal obstruction with bowel function and/or nutrition * Grade 2 or greater peripheral neuropathy * Participation in an investigational study within three weeks * History of anaphylactic shock to prior platinum chemotherapy * History of psychiatric disability or other central nervous system disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the response rate of carboplatin in combination with pemetrexed in patients with recurrent platinum-sensitive epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer. | 2 years | This study has now been published: Matulonis U.A.,Horowitz N, Campos S, Lee H., Lee J., Krasner C., Berlin S., Roche M., Duska L, Pereira L, Kendall D, Penson R. Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer. J Clin Oncol. 2008:26(35):5761-6 |
Secondary
| Measure | Time frame |
|---|---|
| To assess time to progression, progression-free survival, and overall survival in this patient population | — |
| to assess toxicities of treatment with combination carboplatin and pemetrexed. | 2 years |
Countries
United States
Outcome results
None listed